ARCELLX, INC. AMENDED AND RESTATED STANDSTILL AND STOCK RESTRICTION AGREEMENTStandstill and Stock Restriction Agreement • February 28th, 2024 • Arcellx, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amended and Restated Standstill and Stock Restriction Agreement (this “Agreement”) is being entered into as of November 15, 2023 (“Effective Date”) by and among Arcellx, Inc., a Delaware corporation (the “Company”) and Gilead Sciences, Inc., a Delaware corporation (the “Investor”), which amends and restates that certain Standstill and Stock Restriction Agreement (the “Original Standstill Agreement”), dated December 8, 2022.
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • February 28th, 2024 • Arcellx, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of November 15, 2023 by and among Arcellx, Inc., a Delaware corporation (the “Company”), and Gilead Sciences, Inc., a Delaware corporation (the “Investor”).
AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • February 28th, 2024 • Arcellx, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 (this “Amendment No. 1”) is executed as of the Amendment No. 1 Execution Date (as defined below) by and between Arcellx, Inc., a Delaware corporation (“Arcellx”), and Kite Pharma, Inc., a Delaware corporation (“Kite”). Arcellx and Kite are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
